Search Results - "BRACHMANN, Rainer"

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors by Jimeno, Antonio, Gordon, Michael, Chugh, Rashmi, Messersmith, Wells, Mendelson, David, Dupont, Jakob, Stagg, Robert, Kapoun, Ann M, Xu, Lu, Uttamsingh, Shailaja, Brachmann, Rainer K, Smith, David C

“…Wnt signaling is implicated in tumor cell dedifferentiation and cancer stem cell function. Ipafricept (OMP-54F28) is a first-in-class recombinant fusion…”
Get full text

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer by Diamond, Jennifer R., Becerra, Carlos, Richards, Donald, Mita, Alain, Osborne, Cynthia, O’Shaughnessy, Joyce, Zhang, Chun, Henner, Randall, Kapoun, Ann M., Xu, Lu, Stagg, Bob, Uttamsingh, Shailaja, Brachmann, Rainer K., Farooki, Azeez, Mita, Monica

“…Purpose Vantictumab is a monoclonal antibody that binds to frizzled (FZD) receptors and inhibits canonical WNT signaling. This phase Ib dose escalation study…”
Get full text

Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer by Dotan, Efrat, Cardin, Dana B, Lenz, Heinz-Josef, Messersmith, Wells, O'Neil, Bert, Cohen, Steven J, Denlinger, Crystal S, Shahda, Safi, Astsaturov, Igor, Kapoun, Ann M, Brachmann, Rainer K, Uttamsingh, Shailaja, Stagg, Robert J, Weekes, Colin

“…The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts…”
Get full text

Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53 by Wang, Ting, Zeng, Jue, Lowe, Craig B, Sellers, Robert G, Salama, Sofie R, Yang, Min, Burgess, Shawn M, Brachmann, Rainer K, Haussler, David

“…The evolutionary forces that establish and hone target gene networks of transcription factors are largely unknown. Transposition of retroelements may play a…”
Get full text

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models by SPOERKE, Jill M, O'BRIEN, Carol, FRIEDMAN, Lori S, ROSS, Leanne, HAMPTON, Garret M, AMLER, Lukas C, SHAMES, David S, LACKNER, Mark R, HUW, Ling, KOEPPEN, Hartmut, FRIDLYAND, Jane, BRACHMANN, Rainer K, HAVERTY, Peter M, PANDITA, Ajay, MOHAN, Sankar, SAMPATH, Deepak

“…Class 1 phosphatidylinositol 3-kinase (PI3K) plays a major role in cell proliferation and survival in a wide variety of human cancers. Here, we investigated…”
Get full text

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors by Weekes, Colin D., Beeram, Muralidhar, Tolcher, Anthony W., Papadopoulos, Kyriakos P., Gore, Lia, Hegde, Priti, Xin, Yan, Yu, Ron, Shih, L. Mason, Xiang, Hong, Brachmann, Rainer K., Patnaik, Amita

“…Summary The human monoclonal antibody MNRP1685A targets the VEGF binding domain of neuropilin-1 (NRP1), a multi-domain receptor necessary for neural…”
Get full text

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors by Patnaik, Amita, LoRusso, Patricia M., Messersmith, Wells A., Papadopoulos, Kyriakos P., Gore, Lia, Beeram, Muralidhar, Ramakrishnan, Vanitha, Kim, Amy H., Beyer, Joseph C., Mason Shih, L., Darbonne, Walter C., Xin, Yan, Yu, Ron, Xiang, Hong, Brachmann, Rainer K., Weekes, Colin D.

“…Purpose MNRP1685A is a human monoclonal antibody that blocks binding of vascular endothelial growth factor (VEGF), VEGF-B, and placental growth factor 2 to…”
Get full text

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers by Dearth, Lawrence R., Qian, Hua, Wang, Ting, Baroni, Timothy E., Zeng, Jue, Chen, Stephanie W., Yi, Sun Young, Brachmann, Rainer K.

“…Over 1000 different mutants of the tumor suppressor protein p53 with one amino acid change in the core domain have been reported in human cancers. In mouse…”
Get full text

Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans by Xin, Yan, Bai, Shuang, Damico-Beyer, Lisa A., Jin, Denise, Liang, Wei-Ching, Wu, Yan, Theil, Frank-Peter, Joshi, Amita, Lu, Yanmei, Lowe, John, Maia, Mauricio, Brachmann, Rainer K., Xiang, Hong

“…Purpose To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer…”
Get full text

p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5 by Kobayashi, Takahiko, Ishida, Junich, Musashi, Manabu, Ota, Shuichi, Yoshida, Takeshi, Shimizu, Yuichi, Chuma, Makoto, Kawakami, Hiroshi, Asaka, Masahiro, Tanaka, Junji, Imamura, Masahiro, Kobayashi, Masanobu, Itoh, Hiroshi, Edamatsu, Hironori, Sutherland, Leslie C., Brachmann, Rainer K.

“…RBM5 (RNA‐binding motif protein 5) is a nuclear RNA binding protein containing 2 RNA recognition motifs. The RBM5 gene is located at the tumor suppressor locus…”
Get full text

Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants by Danziger, Samuel A., Zeng, Jue, Wang, Ying, Brachmann, Rainer K., Lathrop, Richard H.

“…Motivation: Many biomedical projects would benefit from reducing the time and expense of in vitro experimentation by using computer models for in silico…”
Get full text

Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites by HUA QIAN, TING WANG, NAUMOVSKI, Louie, LOPEZ, Charles D, BRACHMANN, Rainer K

“…The tumor suppressor protein p53, once activated, can cause either cell cycle arrest or apoptosis through transactivation of target genes with p53 DNA binding…”
Get full text

A Global Suppressor Motif for p53 Cancer Mutants by Baroni, Timothy E., Wang, Ting, Qian, Hua, Dearth, Lawrence R., Truong, Lan N., Zeng, Jue, Denes, Alec E., Chen, Stephanie W., Brachmann, Rainer K., Korsmeyer, Stanley J.

“…The transcription factor and tumor suppressor protein p53 is frequently inactivated in human cancers. In many cases, p53 gene mutations result in high levels…”
Get full text

Reverse Two-Hybrid and One-Hybrid Systems to Detect Dissociation of Protein-Protein and DNA-Protein Interactions by Vidal, Marc, Brachmann, Rainer K., Fattaey, Ali, Harlow, Ed, Boeke, Jef D.

“…Macromolecular interactions define many biological phenomena. Although genetic methods are available to identify novel protein-protein and DNA-protein…”
Get full text

hADA2a and hADA3 are required for acetylation, transcriptional activity and proliferative effects of beta-catenin by Yang, Min, Waterman, Marian L., Brachmann, Rainer K.

“…Beta-catenin is the key transcriptional activator of the Wnt pathway important for development and tissue homeostasis of multicellular organisms. Its…”
Get full text

Genome wide screens in yeast to identify potential binding sites and target genes of DNA-binding proteins by Zeng, Jue, Yan, Jizhou, Wang, Ting, Mosbrook-Davis, Deborah, Dolan, Kyle T, Christensen, Ryan, Stormo, Gary D, Haussler, David, Lathrop, Richard H, Brachmann, Rainer K, Burgess, Shawn M

“…Knowledge of all binding sites for transcriptional activators and repressors is essential for computationally aided identification of transcriptional networks…”
Get full text

Overexpression of the oncoprotein prothymosin α triggers a p53 response that involves p53 acetylation by KOBAYASHI, Takahiko, TING WANG, TANAKA, Junji, IMAMURA, Masahiro, HASEGAWA, Kiminori, TANAKA, Yoshiyuki, BRACHMANN, Rainer K, MAEZAWA, Masaji, KOBAYASHI, Masanobu, OHNISHI, Shunsuke, HATANAKA, Kazuteru, HIGE, Shuhei, SHIMIZU, Yuichi, KATO, Mototsugu, ASAKA, Masahiro

“…Activation of the tumor suppressor protein p53 is a critical cellular response to various stress stimuli and to inappropriate activity of growth-promoting…”
Get full text

hADA3 is required for p53 activity by Wang, Ting, Kobayashi, Takahiko, Takimoto, Rishu, Denes, Alec E., Snyder, Eric L., el-Deiry, Wafik S., Brachmann, Rainer K.

“…The tumor suppressor protein p53 is a transcription factor that is frequently mutated in human cancers. In response to DNA damage, p53 protein is stabilized…”
Get full text

p53 Mutants: the Achilles' Heel of Human Cancers? by Brachmann, Rainer K.

“…Recent scientific discoveries have thrust mutants of the tumor suppressor protein p53 into the forefront of the war on cancer, and hold out eventual hope for a…”
Get full text

Dominant-Negative p53 Mutations Selected in Yeast Hit Cancer Hot Spots by Brachmann, Rainer K., Vidal, Marc, Boeke, Jef D.

“…Clinically important mutant p53 proteins may be tumorigenic through a dominant-negative mechanism or due to a gain-of-function. Examples for both hypotheses…”
Get full text